Mount Sinai diabetes program uses “smart data”
A new joint program with the Mount Sinai Health System and Livongo Health, a consumer digital health company, is expected to help diabetics manage their disease better.
A new joint program with the Mount Sinai Health System and Livongo Health, a consumer digital health company, is expected to help diabetics manage their disease better.
Related: [BLOG]: Obesity drug safety review
The diabetes management program, which is already available to Mount Sinai employees, involves a smart data analytics platform that captures information from a variety of sources, including connected glucose meters, personal devices, electronic health records and medication records.
Relevant and timely insights and alerts are then provided in real-time to the person with diabetes, their network of family and friends, and their Mount Sinai care team.
Related:Telemonitoring reduces diabetes patients' blood sugar levels
The rollout of the program in New York is signficiant, since the Mount Sinai Health System includes approximately 6,100 primary and specialty care physicians; 12 joint-venture ambulatory surgery centers; more than 140 ambulatory practices throughout the five boroughs of New York City, Westchester, Long Island, and Florida; and 31 affiliated community health centers.
"With several hundred thousand individuals covered under our value-based care arrangements, and that number growing rapidly, we are shifting our care models accordingly, and Livongo will play a key role in supporting our efforts to effectively manage diabetes-a chronic health condition that affects more than 10% of New Yorkers,” said Niyum Gandhi, executive vice president and chief population health officer for Mount Sinai Health System.
The program provides an end-to-end ecosystem that empowers people with chronic conditions, including diabetes, to live better, including Livongo’s smart data tools. “With our connected technology, real-time data, and predictive analytics, we are partnering to bring a robust program to empower thousands of Mount Sinai employees, dependents, and the health consumers Mount Sinai serves, who are challenged with managing diabetes to live better," said Glen Tullman, CEO of Livongo Health.
Read next: Portal provides diabetes genetic data
FDA Approves Two More Denosumab Biosimilars, Conexxence and Bomyntra
March 27th 2025The fourth pair of denosumab biosimilars, Conexxence and Bomyntra, are expected to launch in the United States in mid 2025, as a result of a global settlement with Amgen, according to a company news release.
Read More
FDA Approves First Drug for Excess Hunger in Prader-Willi Syndrome
March 27th 2025Vykat XR will be available in April to treat the intense hunger that is a hallmark of the rare genetic disease Prader-Willi syndrome. The price is based on a patient’s weight, and the average patient in the clinical trials would have had an average annual cost of $466,200 for the first year.
Read More
FDA Approves Amvuttra for ATTR-CM in Extended Label
March 21st 2025This expanded indication for Amvuttra makes it the first and only FDA-approved treatment for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.
Read More
